May 12, 2020 / 4:17 PM / 23 days ago

India's Jubilant signs licensing deal for Gilead's potential COVID-19 drug

May 12 (Reuters) - India’s Jubilant Life Sciences Ltd said on Tuesday it had signed a non-exclusive licensing agreement for selling Gilead Sciences Inc’s experimental COVID-19 treatment remdesivir in 127 countries, including India. Gilead earlier this month received the U.S. Food and Drug Administration’s emergency use authorization for using remdesivir as a treatment against COVID-19, the respiratory illness caused by the novel coronavirus, after the drugmaker provided data showing the drug had helped patients. (Reporting by Manas Mishra in Bengaluru; Editing by Sriraj Kalluvila)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below